Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

被引：0
|
作者：
Philip Q. Bao
Ramesh K. Ramanathan
Alyssa Krasinkas
Nathan Bahary
Barry C. Lembersky
David L. Bartlett
Steven J. Hughes
Kenneth K. Lee
A. James Moser
Herbert J. Zeh
机构：
[1] Stony Brook University Hospital,Department of Surgery
[2] Virginia G. Piper Cancer Center,Department of Pathology
[3] University of Pittsburgh Medical Center,Department of Medical Oncology
[4] University of Pittsburgh Medical Center,Department of Surgery, Division of Surgical Oncology
[5] University of Pittsburgh Medical Center,undefined
来源：
Annals of Surgical Oncology | 2011年 / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：323 / 323
相关论文
共 50 条
  • [31] Phase II study of gemcitabine in patients with advanced pancreatic cancer
    Carmichael, J
    Fink, U
    Russell, RCG
    Spittle, MF
    Harris, AL
    Spiessi, G
    Blatter, J
    BRITISH JOURNAL OF CANCER, 1996, 73 (01) : 101 - 105
  • [32] Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer
    Fan, Katherine Y.
    Wild, Aaron Tyler
    Laheru, Daniel A.
    Pawlik, Timothy M.
    Zheng, Lei
    Dung Thi Le
    Tran, Phuoc T.
    Dholakia, Avani Satish
    Kumar, Rachit
    Ellsworth, Susannah G.
    Hacker-Prietz, Amy
    Rasheed, Zeshaan
    De Jesus-Acosta, Ana
    Weiss, Matthew
    Makary, Martin
    Cameron, John L.
    Hruban, Ralph H.
    Fishman, Elliott K.
    Wolfgang, Christopher Lee
    Herman, Joseph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [33] Adjuvant therapy in resected pancreatic cancer
    Neoptolemos, J. P.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S4 - S4
  • [34] Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma.
    Safran, Howard
    Winter, Kathryn A.
    Abrams, Ross A.
    Regine, William
    Goodman, Karyn A.
    Berger, Adam C.
    Gillin, Michael
    Philip, Agop Philip
    Lowy, Andrew M.
    Wu, Abraham Jing-Ching
    DiPetrillo, Thomas A.
    Corn, Benjamin W.
    Seaward, Samantha A.
    Haddock, Michael G.
    Song, Suisui
    Jiang, Yixing
    Fisher, Barbara Jean
    Katz, Alan W.
    Mehta, Sharmila P.
    Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H. Ko
    Alan P. Venook
    Emily K. Bergsland
    R. Kate Kelley
    W. Michael Korn
    Elizabeth Dito
    Brian Schillinger
    Janet Scott
    Jimmy Hwang
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1051 - 1057
  • [36] A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer
    Hammad, N.
    Philip, P. A.
    Shields, A. F.
    Sarkar, F. H.
    Abruzzese, J. L.
    Kaseb, A. O.
    Javle, M. M.
    Varadhachary, G. R.
    Wolff, R. A.
    El-Rayes, B. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Ko, Andrew H.
    Venook, Alan P.
    Bergsland, Emily K.
    Kelley, R. Kate
    Korn, W. Michael
    Dito, Elizabeth
    Schillinger, Brian
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1051 - 1057
  • [38] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    Hwang, In Gyu
    Jang, Joung-Soon
    Oh, Sung Yong
    Lee, Suee
    Kwon, Hyuk Chan
    Lee, Gyeong Won
    Go, Seil
    Kang, Myoung Hee
    Cha, Young Joo
    Kang, Jung Hun
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2371 - 2376
  • [39] A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer
    In Gyu Hwang
    Joung-Soon Jang
    Sung Yong Oh
    Suee Lee
    Hyuk Chan Kwon
    Gyeong Won Lee
    Seil Go
    Myoung Hee Kang
    Young Joo Cha
    Jung Hun Kang
    Investigational New Drugs, 2012, 30 : 2371 - 2376
  • [40] A Phase II Trial of Erlotinib in Combination With Gemcitabine and Cisplatin for Unresectable Pancreatic Cancer
    Hwang, I. G.
    Jang, J. S.
    Kang, J. H.
    Lee, G. W.
    Go, S. I.
    Kang, M. H.
    Oh, S. Y.
    Lee, S.
    Kwon, H. C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S461 - S461
12345